Good Place. Good Things. Good Time.

Lightstone Ventures Raises $375M Fund to Invest in Early Stage Biotech

Lightstone Ventures Raises 5M Fund to Invest in Early Stage Biotech

What You Should Know:

– Lightstone Ventures today announced the closing of Lightstone Ventures III with $375M in capital commitments, to invest in early-stage companies developing high-impact therapeutics and technologies.

– The new fund was oversubscribed, exceeding the firm’s targeted raise, and included strong support from both new and existing limited partners. With the closing Fund III, Lightstone Ventures also announced the appointments of Christina Isacson, Ph.D., as Partner and Young Kwon, Ph.D., as Operating Partner.

– The Lightstone team has raised over $850 million since inception and has invested in companies such as Alchemab Therapeutics, ALX Oncology (NASDAQ: ALXO), Catamaran Bio, Cyteir Therapeutics (NASDAQ: CYT), Claret Medical (acquired by Boston Scientific), Disarm Therapeutics (acquired by Eli Lilly and Co.), Gemini Therapeutics (NASDAQ: GMTX), LocanaBio, Nimbus, Ra Pharma (acquired by UCB), Tizona (acquired by Gilead Sciences), and Willow.

Search more articles here: Lightstone Ventures Raises $375M Fund to Invest in Early Stage Biotech

Read original article here: Lightstone Ventures Raises $375M Fund to Invest in Early Stage Biotech



Disclaimers and Denial of responsibility..!

Denial of responsibility! TheTopMag.com is an automatic aggregator of all media around the world. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – jamesonline999@gmail.com . The content will be deleted within 72 hours.
You might also like
Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.